Karyopharm Therapeutics Inc (KPTI) — Cash Flow-to-Debt Ratio
Karyopharm Therapeutics Inc (KPTI) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2026, meaning its operating cash flow of $-24.93 Million could theoretically repay 0% of its total liabilities ($441.49 Million) in one year. See Karyopharm Therapeutics Inc (KPTI) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Karyopharm Therapeutics Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Karyopharm Therapeutics Inc across 15 annual periods. For the full cash flow conversion analysis, see KPTI operating cash flow.
Annual Cash Flow-to-Debt Ratio for Karyopharm Therapeutics Inc (2011–2025)
Year-by-year debt coverage analysis for Karyopharm Therapeutics Inc. Check KPTI cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.19x | $-75.37 Million | $401.34 Million | ▲ +48.4% |
| 2024 | -0.36x | $-127.49 Million | $350.44 Million | ▼ -47.8% |
| 2023 | -0.25x | $-92.72 Million | $376.64 Million | ▲ +38.3% |
| 2022 | -0.40x | $-149.55 Million | $374.83 Million | ▼ -43.4% |
| 2021 | -0.28x | $-107.12 Million | $384.98 Million | ▲ +54.4% |
| 2020 | -0.61x | $-160.23 Million | $262.50 Million | ▲ +21.6% |
| 2019 | -0.78x | $-190.82 Million | $245.19 Million | ▲ +22.7% |
| 2018 | -1.01x | $-159.12 Million | $158.02 Million | ▲ +30.6% |
| 2017 | -1.45x | $-73.72 Million | $50.83 Million | ▲ +68.8% |
| 2016 | -4.65x | $-84.39 Million | $18.14 Million | ▲ +15.5% |
| 2015 | -5.51x | $-94.03 Million | $17.08 Million | ▼ -44.9% |
| 2014 | -3.80x | $-51.45 Million | $13.54 Million | ▲ +58.7% |
| 2013 | -9.20x | $-30.29 Million | $3.29 Million | ▼ -1631.6% |
| 2012 | -0.53x | $-15.51 Million | $29.19 Million | ▼ -23.5% |
| 2011 | -0.43x | $-8.55 Million | $19.88 Million | — |